D1 receptor agonists reverse the subchronic phencyclidine (PCP)-induced novel object recognition (NOR) deficit in female rats

Behavioural Brain Research

Volumn 238, Issue 1, 2013, Pages 36-43

  Horiguchi, Masakuni ^a,b,c   Hannaway, Kayleen E ^a   Adelekun, Adesewa E ^a   Huang, Mei ^a,b   Jayathilake, Karu ^a,b   Meltzer, Herbert Y ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

Cognition; D1 receptor; Novel object recognition; Phencyclidine; Schizophrenia; SKF38393

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; TANDOSPIRONE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DECLARATIVE MEMORY; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; FEMALE; LONG EVANS RAT; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RECOGNITION;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; BENZAZEPINES; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; FEMALE; ISOINDOLES; PHENCYCLIDINE; PIPERAZINES; PYRIMIDINES; RATS; RATS, LONG-EVANS; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D1; RECOGNITION (PSYCHOLOGY); SEROTONIN 5-HT1 RECEPTOR AGONISTS;

EID: 84868543767     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.09.030     Document Type: Article

References (65)

1. Kenny J.T., Meltzer H.Y. Attention and higher cortical functions in schizophrenia. Journal of Neuropsychiatry and Clinical Neurosciences 1991, 3(3):269-275.
2. Saykin A.J., Gur R.C., Gur R.E., Mozley P.D., Mozley L.H., Resnick S.M., et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Archives of General Psychiatry 1991, 48(7):618-624.
3. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophrenia Bulletin 1999, 25:233-255.
4. Stone W.A., Hsi X. Declarative memory deficits and schizophrenia: problems and prospects. Neurobiology of Learning and Memory 2011, 96(4):544-552.
5. Keefe R.S., Bilder R.M., Davis S.M., Harvey P.D., Palmer B.W., Gold J.M., et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 2007, 64(6):633-647.
6. Woodward N.D., Purdon S.E., Meltzer H.Y., Zald D.H. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. International Journal of Neuropsychopharmacology 2005, 8(3):457-472.
7. Hagger C., Buckley P., Kenny J.T., Friedman L., Ubogy D., Meltzer H.Y. Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biological Psychiatry 1993, 34:702-712.
8. Bilder R.M., Goldman R.S., Volavka J., Czobor P., Hoptman M., Sheitman B., et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. American Journal of Psychiatry 2002, 159(6):1018-1028.
9. Snigdha S., Horiguchi M., Huang M., Li Z., Shahid M., Neill J.C., et al. Attenuation of phencyclidine-induced object recognition deficits by the combination of atypical antipsychotic drugs and pimavanserin (ACP 103), a 5-hydroxytryptamine(2A) receptor inverse agonist. Journal of Pharmacology and Experimental Therapeutics 2010, 332(2):622-631.
10. Neill J.C., Barnes S., Cook S., Grayson B., Idris N.F., McLean S.L., et al. Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacology & Therapeutics 2010, 128(3):419-432.
11. Coyle J.T. Glutamate and schizophrenia: beyond the dopamine hypothesis. Cellular and Molecular Neurobiology 2006, 26(4-6):365-384.
12. Javitt D.C., Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry 1991, 148(10):1301-1308.
13. Krystal J.H., D'Souza D.C., Petrakis I.L., Belger A., Berman R.M., Charney D.S., et al. NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harvard Review of Psychiatry 1999, 7(3):125-143.
14. Lahti A.C., Koffel B., LaPorte D., Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995, 13:9-19.
15. Lahti A.C., Weiler M.A., Tamara Michaelidis B.A., Parwani A., Tamminga C.A. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 2001, 25(4):455-467.
16. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Research Reviews 2009, 60(2):279-286.
17. Meltzer H.Y., Horiguchi M., Massey B.W. The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment. Psychopharmacology 2011, 213(2-3):289-305.
18. Horiguchi M., Huang M., Meltzer H.Y. Interaction of mGlu(2/3) agonism with clozapine and lurasidone to restore novel object recognition in subchronic phencyclidine-treated rats. Psychopharmacology (Berl) 2011, 217:13-24.
19. Horiguchi M., Meltzer H.Y. The role of 5-HT(1A) receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats. Psychopharmacology (Berl) 2012, 221(2):205-215.
20. Goldman-Rakic P.S., Castner S.A., Svensson T.H., Siever L.J., Williams G.V. Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl) 2004, 174(1):3-16.
21. Gray J.A., Roth B.L. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophrenia Bulletin 2007, 33(5):1100-1119.
22. Mu Q., Johnson K., Morgan P.S., Grenesko E.L., Molnar C.E., Anderson B., et al. A single 20mg dose of the full D1 dopamine agonist dihydrexidine (DAR-0100) increases prefrontal perfusion in schizophrenia. Schizophrenia Research 2007, 94(1-3):332-341.
23. Lidow M.S., Goldman-Rakic P.S., Gallager D.W., Rakic P. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991, 40(3):657-671.
24. Sawaguchi T., Goldman-Rakic P.S. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991, 251(4996):947-950.
25. Okubo Y., Suhara T., Suzuki K., Kobayashi K., Inoue O., Terasaki O., et al. Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 1997, 385(6617):634-636.
26. Kosaka J., Takahashi H., Ito H., Takano A., Fujimura Y., Matsumoto R., et al. Decreased binding of [11C]NNC112 and [11C]SCH23390 in patients with chronic schizophrenia. Life Sciences 2010, 86(21-22):814-818.
27. Abi-Dargham A., Xu X., Thompson J.L., Gil R., Kegeles L.S., Urban N.B., et al. Increased prefrontal cortical D1 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112. Journal of Psychopharmacology 2011, 26(6):794-805.
28. Choi Y.K., Snigdha S., Shahid M., Neill J.C., Tarazi F.I. Subchronic effects of phencyclidine on dopamine and serotonin receptors: implications for schizophrenia. Journal of Molecular Neuroscience 2009, 38(3):227-235.
29. Arvanov V.L., Liang X., Schwartz J., Grossman S., Wang R.Y. Clozapine and haloperidol modulate N-methyl-d-aspartate- and non-N-methyl-d-aspartate receptor-mediated neurotransmission in rat prefrontal cortical neurons in vitro. Journal of Pharmacology and Experimental Therapeutics 1997, 283(1):226-234.
30. Jardemark K., Marcus M.M., Shahid M., Svensson T.H. Effects of asenapine on prefrontal N-methyl-d-aspartate receptor-mediated transmission: involvement of dopamine D1 receptors. Synapse 2010, 64(11):870-874.
31. Goldman-Rakic P.S., Muly E.C., Williams G.V. D(1) receptors in prefrontal cells and circuits. Brain Research. Brain Research Reviews 2000, 31(2-3):295-301.
32. Stewart C.V., Plenz D. Inverted-U profile of dopamine-NMDA-mediated spontaneous avalanche recurrence in superficial layers of rat prefrontal cortex. Journal of Neuroscience 2006, 26(31):8148-8159.
33. Kozlov A.P., Druzin M.Y., Kurzina N.P., Malinina E.P. The role of D1-dependent dopaminergic mechanisms of the frontal cortex in delayed responding in rats. Neuroscience and Behavioral Physiology 2001, 31(4):405-411.
34. Seamans J.K., Floresco S.B., Phillips A.G. D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. Journal of Neuroscience 1998, 18(4):1613-1621.
35. Arnsten A.F., Goldman-Rakic P.S. Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. Archives of General Psychiatry 1998, 55(4):362-368.
36. Zahrt J., Taylor J.R., Mathew R.G., Arnsten A.F. Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. Journal of Neuroscience 1997, 17(21):8528-8535.
37. Cai J.X., Arnsten A.F. Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys. Journal of Pharmacology and Experimental Therapeutics 1997, 283(1):183-189.
38. Callicott J.H., Mattay V.S., Bertolino A., Finn K., Coppola R., Frank J.A., et al. Physiological characteristics of capacity constraints in working memory as revealed by functional MRI. Cerebral Cortex 1999, 9(1):20-26.
39. Gibbs S.E., D'Esposito M. A functional MRI study of the effects of bromocriptine, a dopamine receptor agonist, on component processes of working memory. Psychopharmacology (Berl) 2005, 180(4):644-653.
40. Grayson B.I., Idris N.F., Neill J.C. Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behavioural Brain Research 2007, 184(1):31-38.
41. McLean S.L., Idris N.F., Woolley M.L., Neill J.C. D(1)-like receptor activation improves PCP-induced cognitive deficits in animal models: Implications for mechanisms of improved cognitive function in schizophrenia. European Neuropsychopharmacology 2009, 19(6):440-450.
42. Roberts B.M., Seymour P.A., Schmidt C.J., Williams G.V., Castner S.A. Amelioration of ketamine-induced working memory deficits by dopamine D1 receptor agonists. Psychopharmacology (Berl) 2010, 210(3):407-418.
43. Bubenikova-Valesova V., Svoboda J., Horacek J., Vales K. The effect of a full agonist/antagonist of the D1 receptor on locomotor activity, sensorimotor gating and cognitive function in dizocilpine-treated rats. International Journal of Neuropsychopharmacology 2009, 12(7):873-883.
44. Snigdha S., Idris N., Grayson B., Shahid M., Neill J.C. Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism. Psychopharmacology (Berl) 2011, 214(4):843-853.
45. Nagai T., Murai R., Matsui K., Kamei H., Noda Y., Furukawa H., et al. Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors. Psychopharmacology (Berl) 2009, 202(1-3):315-328.
46. Li Z., Ichikawa J., Dai J., Meltzer H.Y. Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain. European Journal of Pharmacology 2004, 93(1-3):75-83.
47. Huang M., Li Z., Dai J., Shahid M., Wong E.H., Meltzer H.Y. Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus. Neuropsychopharmacology 2008, 33(12):2934-2945.
48. Meltzer H.Y., Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Progress in Brain Research 2008, 172:177-197.
49. Barnes S.A., Young J.W., Neill J.C. D1 receptor activation improves vigilance in rats as measured by the 5-choice continuous performance test. Psychopharmacology (Berl) 2012, 220(1):129-141.
50. de Lima M.N., Presti-Torres J., Dornelles A., Scalco F.S., Roesler R., Garcia V.A., et al. Modulatory influence of dopamine receptors on consolidation of object recognition memory. Neurobiology of Learning and Memory 2011, 95(3):305-310.
51. Williams G.V., Castner S.A. Under the curve: critical issues for elucidating D1 receptor function in working memory. Neuroscience 2006, 139(1):263-276.
52. Takahashi H., Kato M., Takano H., Arakawa R., Okumura M., Otsuka T., et al. Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. Journal of Neuroscience 2008, 28(46):12032-12038.
53. Cools R., D'Esposito M. Inverted-U-shaped dopamine actions on human working memory and cognitive control. Biological Psychiatry 2011, 69(12):e113-e125.
54. Vijayraghavan S., Wang M., Birnbaum S.G., Williams G.V., Arnsten A.F. Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory. Nature Neuroscience 2007, 10(3):376-384.
55. Takahashi H., Yamada M., Suhara T. Functional significance of central D1 receptors in cognition: beyond working memory. Journal of Cerebral Blood Flow and Metabolism 2012, 32(7):1248-1258.
56. Slifstein M., Kolachana B., Simpson E.H., Tabares P., Cheng B., Duvall M., et al. COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Molecular Psychiatry 2008, 13(August (8)):821-827.
57. Stuchlik A., Vales K. Effect of dopamine D1 receptor antagonist SCH23390 and D1 agonist A77636 on active allothetic place avoidance, a spatial cognition task. Behavioural Brain Research 2006, 172(2):250-255.
58. Murphy B.L., Arnsten A.F., Goldman-Rakic P.S., Roth R.H. Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats monkeys. Proceedings of the National Academy of Sciences of the United States of America 1996, 93(3):1325-1329.
59. Clausen B., Schachtman T.R., Mark L.T., Reinholdt M., Christoffersen G.R. Impairments of exploration and memory after systemic or prelimbic D1-receptor antagonism in rats. Behavioural Brain Research 2011, 223(2):241-254.
60. Chen G., Greengard P., Yan Z. Potentiation of NMDA receptor currents by dopamine D1 receptors in prefrontal cortex. Proceedings of the National Academy of Sciences of the United States of America 2004, 101(8):2596-2600.
61. Kisilevsky A.E., Mulligan S.J., Altier C., Iftinca M.C., Varela D., Tai C., et al. D1 receptors physically interact with N-type calcium channels to regulate channel distribution and dendritic calcium entry. Neuron 2008, 58(4):557-570.
62. Krystal J.H., Mathew S.J., D'Souza D.C., Garakani A., Gunduz-Bruce H., Charney D.S. Potential psychiatric applications of metabotropic glutamate receptor agonists and antagonists. CNS Drugs 2010, 24(8):669-693.
63. Yoshino T., Nisijima K., Katoh S., Yui K., Nakamura M. Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex. Neurochemistry International 2002, 40(4):355-360.
64. Lladó-Pelfort L., Assié M.B., Newman-Tancredi A., Artigas F., Celada P. Preferential in vivo action of F15599, a novel 5-HT(1A) receptor agonist, at postsynaptic 5-HT(1A) receptors. British Journal of Pharmacology 2010, 160(8):1929-1940.
65. González-Maeso J., Ang R.L., Yuen T., Chan P., Weisstaub N.V., López-Giménez J.F., et al. Identification of a serotonin/glutamate receptor complex implicated in psychosis. Nature 2008, 452(7183):93-97.